An Overview of Vasculogenic Mimicry in Breast Cancer.

Autor:	Andonegui-Elguera MA; Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Mexico City, Mexico., Alfaro-Mora Y; Departamento de Genética y Biología Molecular, Centro de Investigación y de Estudios Avanzados del IPN, Mexico City, Mexico., Cáceres-Gutiérrez R; Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Mexico City, Mexico., Caro-Sánchez CHS; Departamento de Patología, Instituto Nacional de Cancerología (INCAN), Mexico City, Mexico., Herrera LA; Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Mexico City, Mexico.; Dirección General, Instituto Nacional de Medicina Genómica, Mexico City, Mexico., Díaz-Chávez J; Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Mexico City, Mexico.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2020 Feb 27; Vol. 10, pp. 220. Date of Electronic Publication: 2020 Feb 27 (Print Publication: 2020).
DOI:	10.3389/fonc.2020.00220
Abstrakt:	Vasculogenic mimicry (VM) is the formation of vascular channels lacking endothelial cells. These channels are lined by tumor cells with cancer stem cell features, positive for periodic acid-Schiff, and negative for CD31 staining. The term VM was introduced by Maniotis et al. (1), who reported this phenomenon in highly aggressive uveal melanomas; since then, VM has been associated with poor prognosis, tumor aggressiveness, metastasis, and drug resistance in several tumors, including breast cancer. It is proposed that VM and angiogenesis (the de novo formation of blood vessels from the established vasculature by endothelial cells, which is observed in several tumors) rely on some common mechanisms. Furthermore, it is also suggested that VM could constitute a means to circumvent anti-angiogenic treatment in cancer. Therefore, it is important to determinant the factors that dictate the onset of VM. In this review, we describe the current understanding of VM formation in breast cancer, including specific signaling pathways, and cancer stem cells. In addition, we discuss the clinical significance of VM in prognosis and new opportunities of VM as a target for breast cancer therapy. (Copyright © 2020 Andonegui-Elguera, Alfaro-Mora, Cáceres-Gutiérrez, Caro-Sánchez, Herrera and Díaz-Chávez.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu